During the last session, Ensysce Biosciences Inc (NASDAQ:ENSC)’s traded shares were 1.15 million, with the beta value of the company hitting 0.67. At the end of the trading day, the stock’s price was $0.66, reflecting an intraday loss of -3.26% or -$0.02. The 52-week high for the ENSC share is $2.06, that puts it down -212.12 from that peak though still a striking 78.79% gain since the share price plummeted to a 52-week low of $0.14. The company’s market capitalization is $12.84M, and the average intraday trading volume over the past 10 days was 19.83 million shares, and the average trade volume was 27.63 million shares over the past three months.
Ensysce Biosciences Inc (ENSC) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. ENSC has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.13.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ensysce Biosciences Inc (NASDAQ:ENSC) trade information
Ensysce Biosciences Inc (ENSC) registered a -3.26% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -3.26% in intraday trading to $0.66, hitting a weekly high. The stock’s 5-day price performance is -7.52%, and it has moved by 21.65% in 30 days. Based on these gigs, the overall price performance for the year is -27.14%. The short interest in Ensysce Biosciences Inc (NASDAQ:ENSC) is 6.35 million shares and it means that shorts have 0.12 day(s) to cover.
Ensysce Biosciences Inc (ENSC) estimates and forecasts
Statistics show that Ensysce Biosciences Inc has outperformed its competitors in share price, compared to the industry in which it operates. Ensysce Biosciences Inc (ENSC) shares have gone up 2.97% during the last six months, with a year-to-date growth rate more than the industry average at 82.30% against 18.10. In the rating firms’ projections, revenue will increase 86.06% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 245k as predicted by 2 analyst(s). As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 515.03k and 305.72k respectively. In this case, analysts expect current quarter sales to shrink by -52.43% and then drop by -100.00% in the coming quarter.
While earnings are projected to return 82.30% in 2024.
ENSC Dividends
Ensysce Biosciences Inc is due to release its next quarterly earnings in December. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Ensysce Biosciences Inc (NASDAQ:ENSC)’s Major holders
Ensysce Biosciences Inc insiders own 1.17% of total outstanding shares while institutional holders control 22.26%, with the float percentage being 22.53%. PLANTE MORAN FINANCIAL ADVISORS, LLC is the largest shareholder of the company, while 14.0 institutions own stock in it. As of 2024-06-30, the company held over 20.0 shares (or 0.0004% of all shares), a total value of $10.0 in shares.
